118 related articles for article (PubMed ID: 38431352)
21. Adjunctive Traditional Chinese Medicine Improves Survival in Patients With Advanced Lung Adenocarcinoma Treated With First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs): A Nationwide, Population-Based Cohort Study.
Li CL; Hsia TC; Li CH; Chen KJ; Yang YH; Yang ST
Integr Cancer Ther; 2019; 18():1534735419827079. PubMed ID: 30836771
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases.
Ke SB; Qiu H; Chen JM; Shi W; Chen YS
Curr Med Sci; 2018 Dec; 38(6):1062-1068. PubMed ID: 30536070
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of serum EGFR gene mutation and serum tumor markers in predicting tyrosine kinase inhibitor efficacy in lung adenocarcinoma.
Feng LX; Wang J; Yu Z; Song SA; Zhai WX; Dong SH; Yu HS; Zhang Y
Clin Transl Oncol; 2019 Aug; 21(8):1005-1013. PubMed ID: 30637712
[TBL] [Abstract][Full Text] [Related]
24. Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation.
Urbán L; Dóczi R; Vodicska B; Tihanyi D; Horváth M; Kormos D; Takács I; Pápai-Székely Z; Póka-Farkas Z; Várkondi E; Schwáb R; Hegedüs C; Vályi-Nagy I; Peták I
Clin Lung Cancer; 2021 Jan; 22(1):e112-e115. PubMed ID: 33082101
[No Abstract] [Full Text] [Related]
25. Quantitative targeted proteomic analysis of potential markers of tyrosine kinase inhibitor (TKI) sensitivity in EGFR mutated lung adenocarcinoma.
Awasthi S; Maity T; Oyler BL; Qi Y; Zhang X; Goodlett DR; Guha U
J Proteomics; 2018 Oct; 189():48-59. PubMed ID: 29660496
[TBL] [Abstract][Full Text] [Related]
26. Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas.
Zhang B; Wang S; Qian J; Yang W; Qian F; Lu J; Zhang Y; Qiao R; Han B
Cancer; 2018 Jun; 124(11):2399-2406. PubMed ID: 29543321
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of 3rd generation TKI in patients with EGFR mutation lung adenocarcinoma with bone metastases: A review of 3 case reports and literature.
Guo Q; Feng W; Hu S; Ye J; Wang S; Su L; Zhang Y; Zhang D; Zhang W; Xu J; Wei Y
Medicine (Baltimore); 2023 Aug; 102(34):e34545. PubMed ID: 37653755
[TBL] [Abstract][Full Text] [Related]
28. High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients.
Hsu KH; Huang YH; Tseng JS; Chen KC; Ku WH; Su KY; Chen JJW; Chen HW; Yu SL; Yang TY; Chang GC
Lung Cancer; 2019 Jan; 127():37-43. PubMed ID: 30642549
[TBL] [Abstract][Full Text] [Related]
29. Transformation of advanced lung adenocarcinoma to acquired T790M resistance mutation adenosquamous carcinoma following tyrosine kinase inhibitor: a case report.
Liu Q; Wu L; Zhang S
Tumori; 2021 Dec; 107(6):NP5-NP10. PubMed ID: 33896242
[TBL] [Abstract][Full Text] [Related]
30. Lung Adenocarcinoma With Primary LIMD1-BRAF Fusion Treated With MEK Inhibitor: A Case Report.
Wang CY; Hsia JY; Li CH; Ho CC; Chao WR; Wu MF
Clin Lung Cancer; 2021 Nov; 22(6):e878-e880. PubMed ID: 34148767
[No Abstract] [Full Text] [Related]
31. Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review.
Zhao N; Zheng SY; Yang JJ; Zhang XC; Xie Z; Xie B; Su J; Chen ZH; Chen SL; Zhang N; Lou NN; Dong S; Wu YL
Clin Lung Cancer; 2015 Mar; 16(2):e5-9. PubMed ID: 25496960
[No Abstract] [Full Text] [Related]
32. Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma.
Dong W; Lei P; Liu X; Li Q; Cheng X
Front Immunol; 2021; 12():686057. PubMed ID: 34804000
[TBL] [Abstract][Full Text] [Related]
33. Drastic antitumor response following administration of afatinib immediately after atezolizumab in a patient with epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer.
Sumi T; Nakata H; Chiba H
Thorac Cancer; 2021 Jul; 12(13):2050-2052. PubMed ID: 34096184
[No Abstract] [Full Text] [Related]
34. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.
Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Su KY; Chang YL; Wu CT; Hsu CC; Liao BC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
Eur J Cancer; 2020 Jan; 124():110-122. PubMed ID: 31760310
[TBL] [Abstract][Full Text] [Related]
35. Salvage Surgery for Advanced Lung Adenocarcinoma After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment.
Lin MW; Yu SL; Hsu YC; Chen YM; Lee YH; Hsiao YJ; Lin JW; Su TJ; Jeffrey Yang CF; Chiang XH; Hsu HH; Chen JS; Hsieh MS
Ann Thorac Surg; 2023 Jul; 116(1):111-119. PubMed ID: 36739067
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy versus personalized therapy for EGFR mutant lung adenocarcinoma resistance to EGFR-tyrosine kinase inhibitors: a retrospective dual-center study.
Jiang K; Wu L; Zheng X; Xu Y; Miao Q; Zheng X; Zhang L; Huang C; Lin G
BMC Pulm Med; 2024 Feb; 24(1):96. PubMed ID: 38402169
[TBL] [Abstract][Full Text] [Related]
37. Human skin biomarkers relationship to response to treatment with tyrosine kinase inhibitors in advanced EGFR-mutated lung adenocarcinoma.
Castañeda-Zárraga A; Rodríguez-Cid JR; Flores-Mariñelarena RR; Trinidad-Bibiano H; Martínez-Herrera JF; Sánchez-Ríos CP; Fernández-Garibay VM; Alatorre-Alexander JA; Martínez-Barrera L; Santillán-Doherty PJ; Vega-Memije ME
Thorac Cancer; 2020 Nov; 11(11):3243-3251. PubMed ID: 33015988
[TBL] [Abstract][Full Text] [Related]
38. Thoracic surgery improved overall survival in patients with stage IIIB-IV epidermal growth factor receptor-mutant lung adenocarcinoma who received and responded to tyrosine kinase inhibitor treatment.
Chien YN; Lin YC; Chang CL; Lin WC; Wu SY
Lung Cancer; 2021 Dec; 162():29-35. PubMed ID: 34662782
[TBL] [Abstract][Full Text] [Related]
39. Primary Resistance to Alectinib Was Lost after Bevacizumab Combined Chemotherapy in ALK-Rearranged Lung Adenocarcinoma.
Nakasuka T; Ichihara E; Makimoto G; Maeda Y; Kiura K
J Thorac Oncol; 2019 Aug; 14(8):e168-e169. PubMed ID: 31345339
[No Abstract] [Full Text] [Related]
40. Pembrolizumab for the better treatment of EGFR-mutant T790M-negative advanced lung adenocarcinoma patients than dual treatment of pemetrexed plus platinum after tyrosine kinase inhibitor treatment failure.
Lu Z; Ye M; Sun T; Wu S; Lin Z; Zhang X; Rao D; Zhang D; Ke Y; Chen Z
Ann Palliat Med; 2022 Jun; 11(6):2100-2109. PubMed ID: 35817745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
